Provided by Tiger Trade Technology Pte. Ltd.

VanEck Pharmaceutical ETF

110.53
-0.6062-0.55%
Post-market: 110.50-0.0338-0.03%17:20 EDT
Volume:97.95K
Turnover:10.83M
Market Cap:1.00B
PE:89.56
High:111.04
Open:110.96
Low:110.01
Close:111.14
52wk High:118.00
52wk Low:85.91
Shares:9.09M
Float Shares:9.09M
Volume Ratio:0.41
T/O Rate:1.08%
Dividend:2.18
Dividend Rate:1.97%
EPS(TTM):1.23
EPS(LYR):0.7765
ROE:--
ROA:--
PB:--
PE(LYR):142.35

Loading ...

Leerink Partners Adjusts Price Target on Merck & Co. to $161 From $127, Keeps Outperform Rating

MT Newswires Live
·
Sep 09

RBC Initiates Novartis at Sector Perform With CHF120 Price Target

MT Newswires Live
·
Sep 09

Merck & Co Inc : Leerink Partners Raises Target Price to $161 from $127

THOMSON REUTERS
·
Sep 09

Merck price target raised to $161 from $127 at Leerink

TIPRANKS
·
Sep 09

Novartis's Stock Selloff Looks Overdone

Dow Jones
·
Sep 09

Novartis Faces Sales Hole in Early 2030s After Trial Setback

Dow Jones
·
Sep 09

Amgen Shares Plunge to Decade Low After Rival Drug Trial Fails, BMO Cuts Rating

Stock News
·
Sep 09

Atai Beckley Holds Shareholder Meeting, Quorum Met with 65.6% Shares Represented

Reuters
·
Sep 09

European Shares Steady as Drugmaker Rout Offsets Commodity Strength

Deep News
·
Sep 09

Merck & Co. Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 09

Asia Morning Call-Global Markets

Reuters
·
Sep 09

Novo Nordisk A/S Stock (NVO) Closed Down by 3.09% on Sep 8: Facts Behind the Movement

TradingKey
·
Sep 09

US Equity Markets End Lower After Houthi Attack on Saudi Arabia Energy Facilities

MT Newswires Live
·
Sep 09

Headlands Research Names Brandon Pallott Chief Commercial Officer

Reuters
·
Sep 09

Eli Lilly Stock (LLY) Falls on Competitor Novartis’ Cholesterol Drug Setback

TIPRANKS
·
Sep 09

Top Midday Decliners

MT Newswires Live
·
Sep 09

Jefferies says definitive readthrough to Sarepta from Novartis news ‘premature’

TIPRANKS
·
Sep 09

GLP1 Drugs Work for Kids, Says Novo Nordisk. They Could be Another Huge Market.

Dow Jones
·
Sep 09

Mizuho sees Sarepta selloff on Novartis DM1 miss as overdone

TIPRANKS
·
Sep 09

Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says

MT Newswires Live
·
Sep 09